Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
CD19 CAR-T cell therapy
Obecabtagene autoleucel (Obe-cel)
Aucatzyl · CD19 CAR-T therapy
CD19 CAR-T for adult B-ALL; renal risk is CRS- and tumor-lysis-associated, with notably lower high-grade CRS.
ModerateCD19 CAR-T cell therapy (fast off-rate binder) · approved 2024
Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL) in adults
Signature kidney injury
Prerenal / Hemodynamic AKI
Obe-cel-specific renal injury rates are not separately well characterized; in the FELIX trial, CRS and immune effector cell-associated neurotoxicity were mostly low grade, with notably low high-grade rates. Across CD19 CAR-T programs, AKI is reported in roughly 5 to 33 percent of patients, driven mainly by CRS-related hemodynamics and tumor lysis, and is usually reversible. In one CAR-T AKI cohort, 18 percent developed AKI, most often from volume depletion or CRS, with renal recovery in the large majority. The lower high-grade CRS rate of obe-cel would be expected to translate into a comparatively lower burden of severe CRS-associated AKI, though direct data are limited.
Source: 39602653
Mechanism of kidney injury
Two linked mechanisms predominate. First, CRS produces fever, vasodilation, capillary leak, and hypotension that lower renal perfusion, causing prerenal azotemia and ischemic tubular injury. Second, rapid lysis of a high leukemic burden can cause tumor lysis syndrome with hyperuricemia and hyperphosphatemia, producing intratubular crystal/cast deposition and metabolic AKI. Obe-cel is not a direct tubular nephrotoxin; the kidney is injured secondarily by the inflammatory and metabolic consequences of effective tumor killing.
Clinical presentation
AKI usually presents during the CRS window with fever, hypotension, rising creatinine, and reduced urine output and a generally bland sediment. When tumor lysis dominates, hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia accompany the creatinine rise.
Anticancer mechanism
Obecabtagene autoleucel is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The CAR uses a fast off-rate (low-affinity) binder designed to reduce excessive T-cell activation, allowing CD19-positive B lymphoblasts to be recognized and killed while limiting toxicity. It received FDA approval in November 2024 for relapsed or refractory adult B-cell acute lymphoblastic leukemia (B-ALL), and is notable for comparatively low rates of high-grade CRS and neurotoxicity.
Management
Treat the driver: for CRS-associated AKI restore perfusion with fluids and vasopressors and give CRS-directed therapy (tocilizumab, corticosteroids per protocol); for tumor lysis use aggressive hydration and urate-lowering therapy with electrolyte correction. Most AKI is hemodynamic and reversible, with renal recovery in the majority; renal replacement therapy is reserved for severe or refractory cases.Lesion-level management framework
Risk factors
- Higher-grade cytokine release syndrome
- High leukemic/tumor burden (tumor lysis risk)
- Pre-existing chronic kidney disease or low baseline GFR
- Volume depletion and hypotension
- Concomitant nephrotoxins, contrast, and elevated baseline LDH
Prevention
- Optimize volume status and renal function before lymphodepletion and infusion
- Tumor lysis prophylaxis (hydration, allopurinol or rasburicase) for high burden
- Early CRS recognition and grading
- Prompt CRS-directed therapy (tocilizumab, corticosteroids) to limit hemodynamic insult
- Avoid stacking nephrotoxins and unnecessary contrast
Clinical depth
Renal dose adjustment
Not applicable in the small-molecule sense - obe-cel is a one-time autologous cell product with no CrCl-based dose thresholds. No renal dose adjustment is established; attention to renal function is warranted for the lymphodepleting chemotherapy and supportive medications given around infusion.
Dialyzability & ESKD dosing
Not applicable. The CAR-T product is a living-cell therapy and is not dialyzable; dialysis serves only to support severe AKI or tumor-lysis metabolic derangements.
Differential diagnosis
Distinguish CRS-driven prerenal/ischemic AKI from tumor lysis syndrome (hyperuricemia, hyperphosphatemia, hyperkalemia) and from lymphodepletion-related or concomitant nephrotoxin injury. Timing relative to CRS and the tumor-lysis lab panel separate the two dominant mechanisms; bland sediment argues against primary glomerular or interstitial disease.
Monitoring
- Serum creatinine and urine output through the CRS window
- CRS grading (fever, hypotension, hypoxia)
- Tumor lysis labs: potassium, phosphate, calcium, uric acid, LDH
- Volume status and weight
- Baseline and serial eGFR
Key trials & series
- FELIX (NCT04404660): pivotal phase 1b/2 of obecabtagene autoleucel in relapsed/refractory adult B-ALL; high response rates with notably low rates of high-grade CRS and neurotoxicity, framing CRS/TLS-associated renal risk as comparatively modest.
Clinical pearls
- Renal risk is CRS- and tumor-lysis-associated, not direct tubular nephrotoxicity from the cells.
- Obe-cel's fast off-rate binder yields lower high-grade CRS, which should translate into comparatively less severe CRS-associated AKI.
- High leukemic burden makes tumor lysis a key early renal threat - prophylax with hydration and urate-lowering therapy.
- Most CAR-T AKI is hemodynamic and reversible; controlling CRS and TLS is the main renal-protective strategy.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Tubular Lumen
The urine flow path
Injury signatures
Prerenal / Hemodynamic AKIElectrolyte Wasting
Beyond the kidney — non-renal toxicities· 3 organ systems
Class-level context for the major non-renal toxicities of cd19 car-t cell therapys.
Immune / Infusion
CRS, infusion reactions, irAEs, anaphylaxis
- Cytokine release syndrome
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
- ICANS / neurotoxicity
Hematologic
Cytopenias, thrombosis, TMA
- Cytopenias, hypogammaglobulinemia
Evidence
5 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkObecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.Roddie C, Sandhu KS, Tholouli E, et al. · N Engl J Med 2024 · PMID 39602653Pivotal FELIX trial supporting approval; documents low rates of high-grade CRS and neurotoxicity that frame the CRS/TLS-associated renal risk.PMIDObecabtagene Autoleucel: First Approval.Lee A. · Mol Diagn Ther 2025 · PMID 39888581Summarizes the CD19 CAR-T mechanism, fast off-rate design, and FDA approval in relapsed/refractory adult B-ALL.PMIDAcute kidney injury following CAR-T cell therapy: a nephrologist's perspective.Kanbay M, Mizrak B, Alper EN, Copur S, Ortiz A. · Clin Kidney J 2024 · PMID 39781479Nephrology review detailing CAR-T-associated AKI mechanisms (CRS, tumor lysis, hemodynamics) and risk factors including grade 3 or higher CRS and low baseline GFR.PMIDAcute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphoma.Sharp J, Zhao Q, Voorhees TJ, et al. · Br J Haematol 2025 · PMID 40589093Cohort quantifying CAR-T AKI incidence (18 percent), etiologies (volume depletion, CRS, tumor lysis), high renal recovery rate, and association with worse survival.PMIDAcute Kidney Injury Associated with Novel Anticancer Therapies: Immunotherapy.Karam S, Ali A, Fung W, Mehta P, Nair S, Anandh U. · Kidney360 2025 · PMID 39992727Class-level onconephrology review of immunotherapy-associated AKI, including CAR-T CRS and immune effector cell mechanisms.
Guidelines & consensus· 17
Expert Panel in Pediatric and Adult Hematologic Malignancies and TLSGuidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based reviewJ Clin Oncol 2008 · PMID 18509186Prevention is the best management: hydration plus prophylactic rasburicase for high-risk patients, hydration plus allopurinol or rasburicase for intermediate-risk, and monitoring for low-risk; for established TLS add aggressive hydration and diuresis plus allopurinol or rasburicase for hyperuricemia. Urinary alkalinization is NOT recommended.International TLS Expert Consensus PanelRecommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensusBr J Haematol 2010 · PMID 20331465Stratify each patient as low/intermediate/high TLS risk using tumor type, bulk/stage, proliferation rate, baseline laboratory TLS, and renal impairment/involvement, then match prophylaxis intensity (monitoring vs allopurinol vs rasburicase) to the assigned risk level.British Committee for Standards in HaematologyGuidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in HaematologyBr J Haematol 2015 · PMID 25876990Risk-adapted prophylaxis and management of TLS in haematological malignancy: hydration with allopurinol for lower-risk and rasburicase for high-risk patients, with monitoring of electrolytes and renal function to prevent and treat AKI.Cairo & Bishop expert proposalTumour lysis syndrome: new therapeutic strategies and classificationBr J Haematol 2004 · PMID 15384972Defines the Cairo-Bishop criteria distinguishing laboratory TLS (>=2 metabolic abnormalities: hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia within 3 days before to 7 days after therapy) from clinical TLS (laboratory TLS plus AKI, cardiac arrhythmia, or seizure), with a severity grading scheme adopted by subsequent guidelines.ASTCTASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsBiol Blood Marrow Transplant 2019 · PMID 30592986Grade CRS by fever, hypotension and hypoxia (grades 1-4) and grade ICANS using the ICE/encephalopathy score plus level of consciousness, seizures, motor findings and raised intracranial pressure/edema; this is the standard severity framework that triggers tocilizumab and corticosteroid escalation in CAR-T and bispecific antibody toxicity (the Lee 2019 consensus).
General onco-nephrology references
Acute Disease Quality InitiativeThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.Cancer Institute NSWIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.Cancer Institute NSWAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.Cancer Institute NSWA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.